Elanco Animal Health (NYSE:ELAN) Cut to “Hold” at Jefferies Financial Group

Jefferies Financial Group lowered shares of Elanco Animal Health (NYSE:ELAN) from a buy rating to a hold rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They currently have $24.00 target price on the stock, down from their previous target price of $31.00.

Several other research analysts also recently weighed in on the company. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. UBS Group raised their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.42.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $22.68 on Tuesday. Elanco Animal Health has a 12-month low of $19.40 and a 12-month high of $27.98. The stock has a market capitalization of $11.33 billion, a P/E ratio of -55.33, a P/E/G ratio of 2.00 and a beta of 1.70. The firm’s 50-day moving average is $23.26 and its two-hundred day moving average is $23.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts predict that Elanco Animal Health will post 1.13 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Kurzius purchased 40,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Herendeen purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the acquisition, the director directly owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This trade represents a 9.83% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 63,198 shares of company stock worth $1,473,109. Company insiders own 1.14% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently made changes to their positions in the business. Anchor Investment Management LLC purchased a new position in shares of Elanco Animal Health in the 2nd quarter valued at $29,000. Integrated Wealth Concepts LLC acquired a new position in shares of Elanco Animal Health during the 2nd quarter valued at $35,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Elanco Animal Health during the 2nd quarter worth $38,000. Root Financial Partners LLC purchased a new stake in Elanco Animal Health during the 3rd quarter worth $41,000. Finally, Bessemer Group Inc. boosted its position in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.